Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Membranous dysmenorrhea: the forgotten entity

D Rabinerson1, B Kaplan, B Fisch

  • 1Department of Obstetrics and Gynecology, Beilinson Medical Center, Petah Tiqva, Israel.

Obstetrics and Gynecology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.

ESMO open·2025
Same author

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO open·2025
Same author

Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years.

Ocular immunology and inflammation·2024
Same author

Preliminary assessment of persistent organic pollutants (POPs) in tissues of Risso's dolphin (Grampus griseus) specimens stranded along the Italian coasts.

Marine pollution bulletin·2022
Same author

Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma.

Cancer cell international·2022
Same author

Corrigendum to "Cast iron street furniture: A historical review" [Endeavour 44 (3) (2020) 100721].

Endeavour·2021
Same journal

The Political Determinants of Obstetric Prescribing.

Obstetrics and gynecology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.

Obstetrics and gynecology·2026
Same journal

Milestones in Motion: Vaginal Birth After Cesarean.

Obstetrics and gynecology·2026
Same journal

Ebola Virus in Pregnancy.

Obstetrics and gynecology·2026
Same journal

A Quality-Improvement Study Evaluating Three Postpartum Prophylactic Oxytocin Rates and Blood Loss After Vaginal Birth.

Obstetrics and gynecology·2026
Same journal

The Effects of Climate Change on Obstetric and Gynecologic Health.

Obstetrics and gynecology·2026
See all related articles

Membranous dysmenorrhea, a rare condition causing painful endometrial shedding, can be triggered by hormonal medications. Discontinuing or adjusting the dosage of offending drugs like Gynera or Provera can resolve symptoms.

Area of Science:

  • Gynecology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Membranous dysmenorrhea is characterized by the expulsion of the endometrium in a single, cast-like piece.
  • This rare gynecological condition is infrequently documented in medical literature.

Observation:

  • Two cases of membranous dysmenorrhea are presented, one associated with the contraceptive Gynera and the other with Provera.
  • Symptoms in the first patient resolved upon discontinuation of Gynera (Gestodene/ethinyl estradiol).
  • The second patient experienced symptom resolution after an increase in her Provera (medroxyprogesterone acetate) dosage.

Findings:

  • Iatrogenic factors, such as hormonal contraceptives and treatments for dysfunctional uterine bleeding, may induce membranous dysmenorrhea.
  • The management of drug-induced membranous dysmenorrhea involves altering the causative medication.

Related Experiment Videos

Implications:

  • This report highlights the importance of considering medication side effects in cases of membranous dysmenorrhea.
  • Clinicians should evaluate patient medication history for potential iatrogenic causes of this condition.
  • Adjusting hormonal therapy can be an effective strategy for managing drug-induced membranous dysmenorrhea.